David E Avigan MD

Clinical Trials

• Interleukin-12 in Treating Women With Metastatic Breast Cancer Who Have Received High-Dose Chemotherapy and Peripheral Stem Cell Transplantation Start of enrollment: 1998 Jun 01

  Unknown status

  Phase 1

• Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer Start of enrollment: 2000 Jul 01

  Withdrawn

  Phase 1, Phase 2

• Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer Start of enrollment: 2001 Oct 01

  Completed

  Phase 2

• Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Start of enrollment: 2006 Dec 01

  Active, not recruiting

  Phase 3

• Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201) Start of enrollment: 2004 Jan 01

  Completed

  Phase 3

• Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2004 Mar 01

  Unknown status

  Phase 2

• Phase I Study of Sequential Cord Blood Transplants Start of enrollment: 2003 May 01

  Completed

  Phase 1

• Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01

  Terminated

  Phase 2

• Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF Start of enrollment: 2004 Oct 01

  Completed

  Phase 1, Phase 2

• Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma Start of enrollment: 2005 Apr 01

  Completed

  Phase 1

• The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma Start of enrollment: 2004 Jul 01

  Completed

  Phase 1

• Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Start of enrollment: 2002 Dec 01

  Completed

  Phase 2

• Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12 Start of enrollment: 2009 Dec 01

  Terminated

  Phase 1, Phase 2

• A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma Start of enrollment: 2002 Dec 01

  Completed

  Phase 1, Phase 2

• The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma Start of enrollment: 2000 Jul 01

  Completed

  Phase 1, Phase 2

• Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Start of enrollment: 1999 Jul 01

  Completed

  Phase 2

• Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant Start of enrollment: 2008 Jun 01

  Completed

  Phase 1

• Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod Start of enrollment: 2008 Aug 01

  Active, not recruiting

  Phase 2

• Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer Start of enrollment: 2008 Sep 01

  Completed

  Not Applicable

• Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

  ACTIVE_NOT_RECRUITING

  PHASE2

• Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

  ACTIVE_NOT_RECRUITING

  PHASE3

• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  RECRUITING

• Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Start of enrollment: 2011 Sep 01

  Terminated

  Phase 1

• Reduced Intensity Double Umbilical Cord Blood Transplantation Start of enrollment: 2011 Dec 01

  Completed

  Phase 2

• PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine Start of enrollment: 2011 Nov 01

  Terminated

  Phase 2

• Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01

  Completed

  Phase 3

• Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma Start of enrollment: 2012 Nov 01

  Completed

  Phase 1

• Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) Start of enrollment: 2013 Mar 01

  Completed

  Phase 2

• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Start of enrollment: 2013 May 16

  Completed

  Phase 1

• Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2014 Mar 03

  Terminated

  Phase 1

• Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04

  COMPLETED

  PHASE3

• A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

  ACTIVE_NOT_RECRUITING

  PHASE1, PHASE2

• Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT Start of enrollment: 2020 Jul 10

  TERMINATED

  PHASE1, PHASE2

• A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2021 May 13

  Active, not recruiting

  Phase 1

• MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05

  Active, not recruiting

  Phase 2

• Elranatamab in R/R Multiple Myeloma Start of enrollment: 2024 Mar 08

  Recruiting

  Phase 2

  Roles: Contact

• Myeloma-Developing Regimens Using Genomics (MyDRUG) Start of enrollment: 2019 Apr 01

  COMPLETED

  PHASE1, PHASE2

  Roles: Contact

• Join now to see all